ArriVent BioPharma Doses First Patient in Phase 1 Trial for Ovarian and Endometrial Cancer Drug
ArriVent BioPharma, Inc. (NASDAQ:AVBP) has given the first dose to a patient in an early-stage U.S. clinical trial for its experimental drug ARR-002. The treatment is a dual-target antibody-drug conjugate aimed at advanced or metastatic ovarian and endometrial cancers. Shares of the company traded at $16.46 following the announcement, down 1.61% for the day.
The experimental drug simultaneously targets two proteins, MUC16 and NaPi2b, which are heavily expressed in ovarian and endometrial tumor cells. By engaging both targets at once, the approach aims to deliver cancer-killing agents more evenly across complex tumor structures where single-target therapies may fail. This trial marks the second antibody-drug conjugate from the company to enter human testing and expands its clinical footprint beyond lung and gastrointestinal cancers.
Investors and market observers will monitor ongoing Phase 1 progress to evaluate the safety, dosage tolerance, and early clinical response in treated patients. ArriVent maintains full development and commercial rights to the drug worldwide outside of Greater China, where regional rights were previously granted to Shanghai Allist Pharmaceuticals Co., Ltd.
Key points
- ArriVent BioPharma dosed the first patient in a U.S. Phase 1 trial testing ARR-002 for ovarian and endometrial cancers.
- ARR-002 is a dual-targeting antibody-drug conjugate aimed at overcoming target variations in solid tumors.
- The trial expands the company's clinical pipeline beyond existing programs in lung and gastrointestinal cancers.
- Shanghai Allist Pharmaceuticals holds exclusive rights to develop and commercialize the drug in Greater China.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is ArriVent BioPharma's ARR-002 drug designed to treat?
ARR-002 is designed to treat advanced or metastatic ovarian and endometrial cancers. It is a dual-target antibody-drug conjugate targeting MUC16 and NaPi2b proteins.
What clinical milestone did ArriVent BioPharma reach for ARR-002?
ArriVent BioPharma dosed its first patient in a Phase 1 clinical trial in the United States to evaluate the safety, tolerability, and effectiveness of ARR-002.
Who holds the rights to ARR-002 in Greater China?
Shanghai Allist Pharmaceuticals Co., Ltd. holds exclusive rights to develop and commercialize ARR-002 in Greater China, while ArriVent retains all other global rights.